Literature DB >> 30598496

Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.

Joseph G Taylor1,2, Andrew Clear3, Maria Calaminici3,4, John G Gribben3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30598496      PMCID： PMC6312038          DOI： 10.3324/haematol.2018.204818

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.

Authors:  Alexander Shimabukuro-Vornhagen; Heinz Haverkamp; Andreas Engert; Leopold Balleisen; Peter Majunke; Günther Heil; Hans Theodor Eich; Harald Stein; Volker Diehl; Andreas Josting
Journal:  J Clin Oncol       Date:  2005-07-11       Impact factor: 44.544

2.  High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Authors:  Peter Hollander; Peter Kamper; Karin Ekstrom Smedby; Gunilla Enblad; Maja Ludvigsen; Julie Mortensen; Rose-Marie Amini; Stephen Hamilton-Dutoit; Francesco d'Amore; Daniel Molin; Ingrid Glimelius
Journal:  Blood Adv       Date:  2017-08-08

3.  Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells.

Authors:  Paul Greaves; Andrew Clear; Andrew Owen; Sameena Iqbal; Abigail Lee; Janet Matthews; Andrew Wilson; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

4.  Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Authors:  Valeria Spina; Alessio Bruscaggin; Annarosa Cuccaro; Maurizio Martini; Martina Di Trani; Gabriela Forestieri; Martina Manzoni; Adalgisa Condoluci; Alberto Arribas; Lodovico Terzi-Di-Bergamo; Silvia Laura Locatelli; Elisa Cupelli; Luca Ceriani; Alden A Moccia; Anastasios Stathis; Luca Nassi; Clara Deambrogi; Fary Diop; Francesca Guidetti; Alessandra Cocomazzi; Salvatore Annunziata; Vittoria Rufini; Alessandro Giordano; Antonino Neri; Renzo Boldorini; Bernhard Gerber; Francesco Bertoni; Michele Ghielmini; Georg Stüssi; Armando Santoro; Franco Cavalli; Emanuele Zucca; Luigi Maria Larocca; Gianluca Gaidano; Stefan Hohaus; Carmelo Carlo-Stella; Davide Rossi
Journal:  Blood       Date:  2018-02-15       Impact factor: 22.113

5.  Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.

Authors:  Stephanie Sasse; Katharina Reddemann; Arjan Diepstra; Ilske Oschlies; Antje Schnitter; Sven Borchmann; Andreas Engert; Peter Borchmann; Wolfram Klapper
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

6.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

7.  Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.

Authors:  Young Wha Koh; Yoon Kyung Jeon; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh
Journal:  Tumour Biol       Date:  2015-12-17

8.  Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.

Authors:  Thomas Menter; Andrea Bodmer-Haecki; Stephan Dirnhofer; Alexandar Tzankov
Journal:  Hum Pathol       Date:  2016-04-01       Impact factor: 3.466

Review 9.  Mechanisms of resistance to immune checkpoint inhibitors.

Authors:  Russell W Jenkins; David A Barbie; Keith T Flaherty
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640
  9 in total
  1 in total

1.  Synergistic Effect of Stereotactic Radiotherapy Combined with Karelizumab on Patients with Advanced NSCLC.

Authors:  Jiayou Guo; Jiayi Guo; Beibei Cheng; Xingbang Sun; Hongwei Zhang; Jianxin Ma
Journal:  J Healthc Eng       Date:  2022-03-08       Impact factor: 2.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.